Home / Markets / News / Select pharma shares gain on tie-up for Pfizer Covid-19 oral treatment drug

Select pharma shares gain on tie-up for Pfizer Covid-19 oral treatment drug

Among individual stocks, Aurobindo Pharma was the top gainer, which rallied 8 per cent to Rs 688.90 on the BSE in intra-day trade.

Premium

3 min read Last Updated : Mar 21 2022 | 12:29 PM IST

Shares of select pharmaceutical companies rallied up to 8 per cent on the BSE in Monday’s intra-day trade after several companies signed voluntary license for Pfizer Inc's Covid-19 oral treatment– nirmatrelvir.

Nirmatrelvir in combination with ritonavir co-pack has received emergency use/conditional authorization for Covid-19 treatment in certain populations by the US FDA and the UK Medicines and Healthcare products Regulatory Agency (UK MHRA and nearly 50 other countries).

Among individual stocks, Aurobindo Pharma was the top gainer, which rallied 8 per cent to Rs 688.90 on the BSE in intra-day trade. The stock has recovered 18 per cent

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in